Semaglutide's patent expires in India and many generic versions launch

Novo Nordisk/Wegovy (semaglutide)

Novo Nordisk's semaglutide patent expired in India on 20 March 2026, and Indian drugmakers including Sun Pharma, Dr. Reddy's, Zydus and Torrent immediately launched cheaper generic versions for diabetes and obesity. It is the first large market where the drug behind Ozempic and Wegovy faces generic competition, marking a shift in global GLP-1 accessibility and pricing.

• Patent expired March 20, 2026; immediate launch of generics by major Indian manufacturers
• Sun Pharma, Dr. Reddy's, Zydus, and Torrent among the companies launching versions
• First large market with generic competition for semaglutide used in Ozempic and Wegovy
• Signals shift in GLP-1 drug pricing and access as patent protection expires in key markets